Skye Bioscience, Inc. Debt Related Commitment Fees and Debt Issuance Costs
Skye Bioscience, Inc. (SKYE) reported Debt Related Commitment Fees and Debt Issuance Costs of $137.19 thousand for the 9-month period ending 2018-09-30, per its 10-Q filed 2019-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts · last filed 2019-11-14
- Skye Bioscience, Inc. debt related commitment fees and debt issuance costs for the quarter ending 2018-09-30 was $1.00.
- Skye Bioscience, Inc. debt related commitment fees and debt issuance costs for the quarter ending 2018-06-30 was $0.00.
- Skye Bioscience, Inc. debt related commitment fees and debt issuance costs for the quarter ending 2018-03-31 was $137.19K.
| Period end | Debt Related Commitment Fees and Debt Issuance Costs 3 month | Debt Related Commitment Fees and Debt Issuance Costs 6 month | Debt Related Commitment Fees and Debt Issuance Costs 9 month |
|---|---|---|---|
| 2018-09-30 | $1.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $1.00 derived: sum of 2 quarters · filed 2019-11-14 | $137.19K 10-Q · filed 2019-11-14 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $137.19K 10-Q · filed 2019-08-09 | |
| 2018-03-31 | $137.19K 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |